S
34.80
5.30 (17.97%)
| Previous Close | 29.50 |
| Open | 30.79 |
| Volume | 22,764 |
| Avg. Volume (3M) | 21,384 |
| Market Cap | 96,945,384 |
| Price / Sales | 3.43 |
| Price / Book | 2.58 |
| 52 Weeks Range | |
| Earnings Date | 14 Nov 2025 |
| Profit Margin | -107.77% |
| Operating Margin (TTM) | -879.63% |
| Diluted EPS (TTM) | -4.70 |
| Quarterly Revenue Growth (YOY) | 121.20% |
| Total Debt/Equity (MRQ) | 5.84% |
| Current Ratio (MRQ) | 5.12 |
| Operating Cash Flow (TTM) | -13.89 M |
| Levered Free Cash Flow (TTM) | -9.91 M |
| Return on Assets (TTM) | -26.82% |
| Return on Equity (TTM) | -49.39% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Sol-Gel Technologies Ltd. | Mixed | Mixed |
AIStockmoo Score
0.5
| Analyst Consensus | NA |
| Insider Activity | NA |
| Price Volatility | -5.0 |
| Technical Moving Averages | 2.5 |
| Technical Oscillators | 4.0 |
| Average | 0.50 |
|
Sol-Gel Technologies Ltd is a dermatology company. It is engaged in identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases. The company's product candidate pipeline consists of silica-based microencapsulation technology platform, and several generic product candidates across multiple indications. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 70.00% |
| % Held by Institutions | 24.29% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Yelin Lapidot Holdings Management Ltd. | 30 Jun 2025 | 17,753 |
| Steward Partners Investment Advisory, Llc | 30 Jun 2025 | 316 |
| Caliber Wealth Management, Llc / Ks | 30 Jun 2025 | 0 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 04 Sep 2025 | Announcement | Sol-Gel Announces Health Canada Approval of EPSOLAY® |
| 15 Aug 2025 | Announcement | Sol-Gel Reports Second Quarter 2025 Financial Results and Provides Corporate Updates |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |